Mustang Bio, Inc.

72 articles with Mustang Bio, Inc.

• Mustang Bio Awarded Massachusetts Life Sciences Center Tax Incentive

  6/17/2021

  Mustang Bio, Inc. announced that it was one of 28 recipients awarded tax incentives from the Massachusetts Life Sciences Center.

• Mustang Bio to Present at the Raymond James Human Health Innovation Conference

  6/16/2021

  Mustang Bio, Inc. today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will present at the Raymond James Human Health Innovation Conference, taking place virtually from June 21 - 23, 2021.

• Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia

  6/11/2021

  Mustang Bio, Inc. announced updated interim data from the ongoing Phase 1/2 clinical trial investigating the safety and efficacy of MB-106 CD20-targeted, autologous CAR T cell therapy for high-risk B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia.

• Mustang Bio to Host Key Opinion Leader Webinar on MB-106 CD20-Targeted CAR T for the Treatment of High-Risk B-Cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia

  6/7/2021

  Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), today announced that it will host a key opinion leader (“KOL”) webinar on MB-106 CD20-targeted CAR T cell therapy,

• 

  Clinical Catch-Up: May 17-21

  5/24/2021

  It was another busy week for clinical trial announcement. Here’s a look.

• Mustang Bio and City of Hope Announce First Patient Dosed in Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors

  5/18/2021

  Mustang Bio, Inc. (“Mustang”) today announced that the first patient has been dosed in a clinical trial to establish the safety and feasibility of administering MB-101 (autologous IL13Rα2-CAR T cells) to patients with leptomeningeal brain tumors (e.g., glioblastoma, ependymoma or medulloblastoma).

• Mustang Bio Reports First Quarter 2021 Financial Results and Recent Corporate Highlights

  5/14/2021

  Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2021.

• Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at European Hematology Association 2021 Virtual Congress

  5/12/2021

  Fred Hutchinson Cancer Research Center to present updated interim data from ongoing MB-106 Phase 1/2 clinical trial

• Mustang Bio Announces FDA Acceptance of IND Application for MB-106, a CD20-Targeted CAR T Therapy

  5/10/2021

  The Phase 1/2 multicenter study to assess the safety, tolerability and efficacy of MB-106 in patients with relapsed or refractory CD20+ B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia is expected to begin enrolling patients in the third quarter of this year

• Mustang Bio to Participate in Chardan’s 5th Annual Genetic Medicines Manufacturing Summit

  4/21/2021

  Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, and Knut Niss, Ph.D., Chief Technology Officer, will participate in Chardan’s 5th Annual Genetic Medicines Manufacturing Summit,

• Mustang Bio Reports Full-Year 2020 Financial Results and Recent Corporate Highlights

  3/24/2021

  Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the full year ended December 31, 2020.

• Mustang Bio to Participate in Three March 2021 Virtual Investor Conferences

  3/4/2021

  Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Mustang’s management team will participate in three virtual investor conferences in March 2021.

• Mustang Bio Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day®

  2/26/2021

  Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced its support for Rare Disease Day®

• 

  Clinical Catch-Up: February 1 – February 5

  2/8/2021

  It was a busy week for clinical trial updates. Here’s a look.

• Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”)

  2/2/2021

  FDA removes clinical hold for pivotal Phase 2 MB-107 clinical trial Company plans to enroll first patient in MB-107 pivotal trial in the second quarter of 2021 Clinical outcomes in investigator-IND XSCID trials continue to show compelling efficacy

• 

  Clinical Trial Updates: Who's Ramping Back Up and Who's Hitting Pause

  2/2/2021

  There were two reported cases of trials restarting and one pausing this week. Here’s a look.

• Mustang Bio and City of Hope Announce Initiation of Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors

  12/21/2020

  Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, and City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, today announced that a Phase 1 single-center, two-arm cl

• Mustang Bio Announces Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

  12/7/2020

  Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced interim data from the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma (“NHL”

• Mustang Bio to Host Key Opinion Leader Call on MB-106 for the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin LymphomaCall to be held Wednesday, December 9, 2020, at 1:00 p.m. EST

  12/1/2020

  Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that it will host a key opinion leader (KOL) call on MB-106 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma on Wednesday, December 9, 2020, at 1:00 p.m

• Mustang Bio Announces Positive Opinion from the European Medicines Agency on Orphan Drug Designation for Its Lentiviral Gene Therapy for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”)

  11/24/2020

  Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the European Commission (“EC”) issued a positive opinion on its application for Orphan Drug Designation for Mustang’s lentiviral gene therapy for the treatment of X-linke